Increasing a biologic's binders from two or four to six or twelve is not an incremental improvement. It creates 'emergent properties of scale.' This high valency allows for sophisticated control over 3D spatial geometry at the cell surface and eliminates the design trade-offs inherent in simpler multispecific molecules.
For complex biologics with many binders, chasing astronomical affinity is counterproductive and risks off-tumor toxicity. A better strategy is to use binders with modest affinity and leverage the massive avidity gained from multiple binding sites. This provides a 'finer dial' to tune specificity and improve the therapeutic window.
Unlike large pharma where novel projects compete with established, safer alternatives, biotech startups derive immense power from their singular focus. The "live or die" mentality on a single hard problem forces teams to innovate and persevere through setbacks, which is essential for pushing true scientific boundaries.
Designing therapeutics with immense combinatorial complexity is impossible through rational design alone. The optimal approach is to first use human biological hypotheses to narrow the vast search space. Then, employ large-scale screening and data analysis to optimize within that constrained space, navigating variables too complex for human comprehension.
Effective drug design must move beyond treating targets as simple points on a cell. The cell surface is a complex "kelp forest" where receptor biophysics—target proximity, orientation, epitope location, and protein flexibility—are critical variables. Understanding this 3D complexity is key to creating powerful, next-generation therapeutics.
Current logic gates in biologics are mostly simple 'AND' gates for safety. Advanced platforms like SynthBody use multi-tiered logic, such as 'AND-better' gates, to summate signals from multiple targets. This not only improves safety but also dramatically boosts efficacy by creating a superior activity profile when multiple targets are present.
The discovery-based model of finding highly impactful single targets like HER2 or PD-1 is becoming unsustainable as the low-hanging fruit is picked. The field must shift toward an engineering-first approach, designing complex, multi-functional therapeutics to achieve specific clinical objectives, much like high-tech fields.
When launching a new technology platform, minimize initial biological risk. Synthetic Design Lab intentionally applied its advanced logic-gating to antibody-drug conjugates (ADCs)—a proven modality—rather than novel immunotherapy. This strategy allowed them to validate the platform's technical power without the confounding variables of complex, unproven biology.